<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625558</url>
  </required_header>
  <id_info>
    <org_study_id>2014-7130</org_study_id>
    <nct_id>NCT02625558</nct_id>
  </id_info>
  <brief_title>Riociguat for Sarcoidosis Associated Pulmonary Hypertension</brief_title>
  <acronym>RioSAPH</acronym>
  <official_title>A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blind placebo controlled trial of riociguat for sarcoidosis associated pulmonary&#xD;
      hypertension&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design Patients will be recruited into double blind randomized trial of riociguat with&#xD;
      1:1 active drug to placebo. The table below summarizes the study design. Patients will have&#xD;
      previously undergone right heart catheterization (RHC) within six months of initial dose&#xD;
      dispensation and with no significant change in treatment for pulmonary hypertension. Patients&#xD;
      will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a&#xD;
      day.&#xD;
&#xD;
      The patient will be treated for 48 weeks or until clinical worsening of disease. An&#xD;
      adjudication committee will review all cases of clinical worsening. This committee will be&#xD;
      blinded to treatment. The determination by the adjudication committee will be used as the&#xD;
      final determinant for the primary end point.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time until clinical worsening</measure>
    <time_frame>48 weeks</time_frame>
    <description>Patient shows deterioration using fixed criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: adverse events</measure>
    <time_frame>48 weeks</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in QOL using general and sarcoidosis specific instruments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six minute walk</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in six minute walk distance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Riociguat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat</intervention_name>
    <description>Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day</description>
    <arm_group_label>Riociguat</arm_group_label>
    <other_name>Rio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given three times a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diagnosis of sarcoidosis&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Life expectancy of at least 2 years.&#xD;
&#xD;
          -  Subjects must be able to understand and be willing to sign the written informed&#xD;
             consent form. A signed informed consent form must be appropriately obtained prior to&#xD;
             the conduct of any trial-specific procedure.&#xD;
&#xD;
          -  Females of reproductive potential (FRP) must have a negative, pre-treatment pregnancy&#xD;
             test.&#xD;
&#xD;
          -  FRP must obtain monthly pregnancy tests during treatment and one month after treatment&#xD;
             discontinuation. Post-menopausal women (defined as no menses for at least 1 year or&#xD;
             post-surgical from bilateral oophorectomy) and surgically sterilized women are not&#xD;
             required to undergo a pregnancy test.&#xD;
&#xD;
          -  Females of reproductive potential and all non-vasectomized male participants must&#xD;
             agree to use reliable contraception when sexually active.&#xD;
&#xD;
          -  Subjects (males and females) of childbearing potential must agree to use adequate&#xD;
             contraception beginning at the signing of the informed consent form (ICF) until at&#xD;
             least 30 days after the last dose of study drug.&#xD;
&#xD;
          -  Willing and able to comply with the protocol, including follow-up visits and&#xD;
             examinations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with an FVC of less than 30% of predicted during screening visit.&#xD;
&#xD;
          -  Patients with severe airway obstruction&#xD;
&#xD;
          -  Patients unable to perform the 6 minute walk test&#xD;
&#xD;
          -  Pregnant women (i.e. positive serum ß-human chorionic gonadotropin test or other signs&#xD;
             of pregnancy),&#xD;
&#xD;
          -  Breast feeding women&#xD;
&#xD;
          -  FRP not using reliable contraception as recommended in the Prescriber Guide for the&#xD;
             riociguat pregnancy monitoring program&#xD;
&#xD;
          -  Subjects with a medical disorder, condition, or history of such that would impair the&#xD;
             subject's ability to participate or complete this study in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  Known significant left heart disease:&#xD;
&#xD;
          -  Pulmonary venous hypertension indicated by baseline pulmonary capillary wedge pressure&#xD;
             &gt; 15 mmHg&#xD;
&#xD;
          -  Active state or history of hemoptysis or pulmonary hemorrhage&#xD;
&#xD;
          -  Subjects requiring nitrates for any reason&#xD;
&#xD;
          -  Subject using nitrates within one month of entering study&#xD;
&#xD;
          -  Pulmonary veno-occlusive disease&#xD;
&#xD;
          -  Subjects with underlying medical disorders with an anticipated life expectancy below 2&#xD;
             years (e.g. active cancer disease with localized and/or metastasized tumor).&#xD;
&#xD;
          -  Subjects with hypersensitivity to the investigational drug or any of the excipients.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Severe proven or suspected coronary artery disease&#xD;
&#xD;
          -  Clinical relevant hepatic dysfunction indicated by: bilirubin &gt;2 times upper limit&#xD;
             normal at Visit 0 and/or: alanine aminotransferase (ALT) or AST aspartate&#xD;
             aminotransferase (AST) &gt;3 times upper limit normal at Visit 0 and/or: signs of severe&#xD;
             hepatic insufficiency (e.g. impaired albumin synthesis with an albumin &lt;32 g/L,&#xD;
             hepatic encephalopathy &gt; grade 1a) at Visit 0&#xD;
&#xD;
        West Haven Criteria of Altered Mental Status in Hepatic Encephalopathy&#xD;
&#xD;
          -  Severe renal insufficiency indicated by a glomerular filtration rate &lt;30 mL/min at&#xD;
             Visit 0, e.g. calculated based on the Cockcroft formula or the Modification of Diet in&#xD;
             Renal Disease Study Group (MDRD) formula&#xD;
&#xD;
          -  Inability to comply with the protocol and/or not willing or not available for&#xD;
             follow-up assessments.&#xD;
&#xD;
          -  Any condition which, in the investigator's opinion, makes the subject unsuitable for&#xD;
             trial participation.&#xD;
&#xD;
        Excluded therapies and medications, previous and concomitant&#xD;
&#xD;
          -  Specific (e.g. sildenafil or tadalafil) or unspecific phosphodiesterase inhibitors&#xD;
             (e.g. dipyridamole, theophylline).&#xD;
&#xD;
          -  NO donors (e.g. nitrates). Single applications of vasoactive drugs in connection with&#xD;
             diagnostic vasoreactive testing are allowed.&#xD;
&#xD;
          -  Concurrent use of another investigational drug or device therapy (i.e., outside of&#xD;
             study treatment) during, or within 4 weeks of trial entry (signing of the informed&#xD;
             consent form).&#xD;
&#xD;
          -  Major surgery within 30 days prior to start of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P Baughman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Nathan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inova Fairfax Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert P Baughman, MD</last_name>
    <phone>513-584-5225</phone>
    <email>bob.baughman@uc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicia Thompson</last_name>
      <phone>513-584-6252</phone>
      <email>THOMPSFA@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert P Baughman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>December 4, 2015</last_update_submitted>
  <last_update_submitted_qc>December 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Robert P Baughman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>riociguat</keyword>
  <keyword>saph</keyword>
  <keyword>sarcoidosis</keyword>
  <keyword>sarcoidosis associated pulmonary hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riociguat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

